Physician profile
Peter Sukin
NPI 1932178787
$2,413.21
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $228 · 2021: $237 · 2022: $346 · 2023: $578 · 2024: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $357.16 | 2019-2023 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $350.97 | 2022-2024 | Caplyta |
| Allergan, INC. | $297.55 | 2019-2020 | |
| Axsome Therapeutics, INC. | $248.41 | 2023 | Auvelity |
| Alkermes, INC. | $240.22 | 2019-2024 | Lybalvi |
| Ironshore Pharmaceuticals INC. | $233.96 | 2019-2021 | |
| Abbvie INC. | $219.31 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $166.64 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $114.85 | 2019 | |
| Neuronetics, INC. | $93.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sukin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.